We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Verici Dx plc,today announced that it has signed an exclusive global licensing agreement with Thermo Fisher Scientific, to further develop an assay for pre-transplant prognostic testing for risk of early kidney rejection.
Among older men with prostate cancer, an organ transplant is associated with higher overall mortality, but not prostate cancer-specific mortality (PCSM)